Clinical trial analysis of 2019-nCoV therapy registered in China

被引:81
作者
Zhang, Qi [1 ]
Wang, Yakun [1 ]
Qi, Changsong [1 ]
Shen, Lin [1 ]
Li, Jian [1 ]
机构
[1] Peking Univ, Canc Hosp & Inst, Key Lab Carcinogenesis & Translat Res, Dept Gastrointestinal Oncol,Minist Educ, Fucheng Rd 52, Beijing 100142, Peoples R China
关键词
China; clinical trial; new coronavirus pneumonia; new drugs;
D O I
10.1002/jmv.25733
中图分类号
Q93 [微生物学];
学科分类号
071005 [微生物学];
摘要
So far, there is a lack of effective drugs for the new coronavirus pneumonia. With more and more patients diagnosed, China has carried out more than 100 clinical studies of new coronavirus infection, including antiviral drugs, antimalarial drugs, glucocorticoids, plasma therapy, virus vaccine, and other Western drugs, while Chinese medicine research accounted for half of the studies. Most of the trials were initiated by investigators and the study period would last for 1 to 11 months. The primary endpoints included symptom improvement and virus nucleic acid turning negative, but the optimal endpoint has not been determined. Although the final results of studies will take a long time to complete, the interim research data may provide some help for the current urgent demand for drug treatment. Compared with that of during SARS period in 2003, China has the stronger capability to carry out clinical trials of new drugs in emergency period.
引用
收藏
页码:540 / 545
页数:6
相关论文
共 8 条
[1]
[Anonymous], LANCET ONCOL S
[2]
[Anonymous], 2020, RUSSIAS CLAIM SUCCES
[3]
Chung MS, 2020, EUR RADIOL, V30, P2182, DOI [10.1007/s00330-019-06574-1, 10.1148/radiol.2020200230]
[4]
Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR (Publication with Expression of Concern) [J].
Corman, Victor M. ;
Landt, Olfert ;
Kaiser, Marco ;
Molenkamp, Richard ;
Meijer, Adam ;
Chu, Daniel K. W. ;
Bleicker, Tobias ;
Bruenink, Sebastian ;
Schneider, Julia ;
Schmidt, Marie Luisa ;
Mulders, Daphne G. J. C. ;
Haagmans, Bart L. ;
van der Veer, Bas ;
van den Brink, Sharon ;
Wijsman, Lisa ;
Goderski, Gabriel ;
Romette, Jean-Louis ;
Ellis, Joanna ;
Zambon, Maria ;
Peiris, Malik ;
Goossens, Herman ;
Reusken, Chantal ;
Koopmans, Marion P. G. ;
Drosten, Christian .
EUROSURVEILLANCE, 2020, 25 (03) :23-30
[5]
First Case of 2019 Novel Coronavirus in the United States [J].
Holshue, Michelle L. ;
DeBolt, Chas ;
Lindquist, Scott ;
Lofy, Kathy H. ;
Wiesman, John ;
Bruce, Hollianne ;
Spitters, Christopher ;
Ericson, Keith ;
Wilkerson, Sara ;
Tural, Ahmet ;
Diaz, George ;
Cohn, Amanda ;
Fox, LeAnne ;
Patel, Anita ;
Gerber, Susan I. ;
Kim, Lindsay ;
Tong, Suxiang ;
Lu, Xiaoyan ;
Lindstrom, Steve ;
Pallansch, Mark A. ;
Weldon, William C. ;
Biggs, Holly M. ;
Uyeki, Timothy M. ;
Pillai, Satish K. .
NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (10) :929-936
[6]
High-Throughput Screening and Identification of Potent Broad-Spectrum Inhibitors of Coronaviruses [J].
Shen, Liang ;
Niu, Junwei ;
Wang, Chunhua ;
Huang, Baoying ;
Wang, Wenling ;
Zhu, Na ;
Deng, Yao ;
Wang, Huijuan ;
Ye, Fei ;
Cen, Shan ;
Tan, Wenjie .
JOURNAL OF VIROLOGY, 2019, 93 (12)
[7]
SARS: Systematic review of treatment effects [J].
Stockman, Lauren J. ;
Bellamy, Richard ;
Garner, Paul .
PLOS MEDICINE, 2006, 3 (09) :1525-1531
[8]
Chloroquine is a potent inhibitor of SARS coronavirus infection and spread [J].
Vincent, Martin J. ;
Bergeron, Eric ;
Benjannet, Suzanne ;
Erickson, Bobbie R. ;
Rollin, Pierre E. ;
Ksiazek, Thomas G. ;
Seidah, Nabil G. ;
Nichol, Stuart T. .
VIROLOGY JOURNAL, 2005, 2 (1)